Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic supplementation in autoimmune uveitis (12‑month follow‑up)
2024-517946-32-00Phase 2Authorised
- Sponsor
- General University Hospital in Prague
- Start
- Dec 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of escherichia coli nissle 1917 in noninfectious uveitis (NIU), sponsored by General University Hospital in Prague. Primary endpoint: Time to first disease relapse from the baseline visit (V2). Planned start Dec 2024; status: authorised.
02
Drugs
escherichia coli nissle 1917
03
Conditions
noninfectious uveitis (NIU)
Beyond the preview
Go deeper on 2024-517946-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517946-32-00.